Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection Human proof of concept data in multiple clinical settings – including oncology, autoimmune diseases, and type 1 diabetes – expected in 2023 and 2024 IND submitted to investigate SC291 in multiple B-cell-mediated autoimmune diseases with initial proof of concept data expected in 2024 Enrollment contin
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer, and Nate Hardy, Sana’s Chief Financial Officer. Steve Harr will present at Citi’s 18th Annual BioPharma Conferenc
Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted all